Sat. Jan 28th, 2023
HIV prevention drug

ETHIOPIANS TODAY, ADDIS ABABA (FINFINNEE), ETHIOPIA:

 211 total views,  1 views today

Zimbabwe becomes first African nation to approve HIV prevention drug -the guardian

World Health Organization welcomes country’s ‘crucial step’ in backing use of long-acting injectable cabotegravir (CAB-LA).

Zimbabwe first African nation to approve crucial HIV prevention drug • FRANCE 24 English

Zimbabwe has become the first country in Africa and the third in the world to approve an HIV prevention drug recently recommended by the World Health Organization (WHO).

Regulators in Australia and the US have already given their backing to use the long-acting injectable cabotegravir (CAB-LA), and the WHO welcomed the move by Zimbabwe.

The country’s fight against HIV has seen Aids-related deaths fall from an estimated 130,000 in 2002 to 20,000 in 2021.

Last year it launched a strategic plan to end Aids by 2030 and has already reached a target known as 90-90-90 – 90% of people living with HIV knowing their status; 90% getting antiretroviral treatment; and 90% having the virus suppressed.

Zimbabwe’s healthcare system is facing extreme difficulties amid the country’s economic crisis and no one at the Ministry of Health was available to comment on the new medicine.

The WHO said in a statement that regulatory approval was a “crucial step”, adding that it would support Zimbabwe “to design and develop programmes so that CAB-LA can be implemented, safely and effectively, for greatest impact”.

The drug has renewed hopes of further reducing deaths in southern Africa and follows the WHO’s recommendation in July that CAB-LA is highly effective at reducing transmission among people at most risk of contracting HIV.

Nyasha Sithole, of the Development Agenda for Girls and Women in Africa (DAWA) network, said: “Accelerating HIV prevention for girls and young women requires an expansion on choices available. I am excited and proud to know that my own country has approved the use of CAB-LA. This will contribute to our basket of HIV prevention tools that work for us as girls and women in Zimbabwe.”

… we have a small favour to ask. Millions are turning to the Guardian for open, independent, quality news every day, and readers in 180 countries around the world now support us financially.

We believe everyone deserves access to information that’s grounded in science and truth, and analysis rooted in authority and integrity. That’s why we made a different choice: to keep our reporting open for all readers, regardless of where they live or what they can afford to pay. This means more people can be better informed, united, and inspired to take meaningful action.

In these perilous times, a truth-seeking global news organisation like the Guardian is essential. We have no shareholders or billionaire owner, meaning our journalism is free from commercial and political influence – this makes us different. When it’s never been more important, our independence allows us to fearlessly investigate, challenge and expose those in power.

theguardian

Follow us on:

Telegram: https://t.me/ethiopianstoday

Facebook: https://www.facebook.com/ethiopianstoday

Twitter: https://twitter.com/ethiopianstoday

Instagram: https://www.instagram.com/ethiopianstoday1

Pinterest: https://www.pinterest.com/ethiopianstoday

YouTube: https://www.youtube.com/channel/UC8CrAEUV9Buhu1qaKgptscQ

Google News: https://news.google.com/publications/CAAqBwgKMMf5qQswuYTCAw

 

By Chala Dandessa

I am freelancer and Editor at ETHIOPIANS TODAY website. If you have any comment use caalaadd2@gmail.com as email contact. Additionally you can contact us through the contact page of www.ethiopianstoday.com. Twitter https://www.twitter.com/caalaadd Instagram: https://www.intagram.com/caalaadd Facebook: https://www.facebook.com/caalaaddofficial

Leave a Reply